Larimar Therapeutics (LRMR) Operating Expenses (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Operating Expenses for 14 consecutive years, with $34.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 23.6% year-over-year to $34.4 million; the trailing twelve-month figure through Jun 2026 stood at $175.7 million (up 61.84% YoY), and the FY2025 full-year result was $172.5 million, up 89.79% from the prior year.
• Operating Expenses declined to $34.4 million in Q2 2026 per LRMR's latest filing, from $64.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $64.0 million in Q4 2025 and bottomed at $7.6 million in Q1 2023.
• Historically, Operating Expenses has averaged $22.1 million across 5 years, with a median of $16.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses plunged 49.12% in 2022, then jumped 171.02% in 2025.
• Over 5 years, Operating Expenses stood at $10.4 million in 2022, then jumped by 35.66% to $14.2 million in 2023, then soared by 120.96% to $31.3 million in 2024, then surged by 104.58% to $64.0 million in 2025, then plunged by 46.34% to $34.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $34.4 million, $64.0 million, and $49.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.